Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Secondary Hypogonadism
Interventions
DRUG

enclomiphene citrate

oral, capsules, taken one time daily, for 3 months

DRUG

Placebo

Oral capsule taken one time daily for 3 months

Trial Locations (13)

14609

Rochester Clinical Research, Rochester

29464

Coastal Carolina Research Center, Mt. Pleasant

33024

All Medical Research, Cooper City

33134

Clinical Research of South Florida, Coral Gables

33169

Phase One Solutions, Miami Gardens

34208

Meridien Research, Bradenton

36608

Coastal Clinical Research, Mobile

37920

New Orleans Center for Clinical Research, Knoxville

40509

Central Kentucky Research Associates, Lexington

72205

Baptist Health Center for Clinical Research, Little Rock

84020

Lone Peak Family Medicine, Draper

84065

Granger Medical Clinic, Riverton

91730

Rancho Cucamonga Clinical Trials, Rancho Cucamonga

All Listed Sponsors
lead

Repros Therapeutics Inc.

INDUSTRY

NCT01739595 - Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism | Biotech Hunter | Biotech Hunter